PolyPid (PYPD) has released an update.
PolyPid Ltd., an Israeli company, is moving forward with a registration statement to sell up to $8.25 million of its ordinary shares under a new sales agreement with Oppenheimer & Co. Inc. This strategic financial move aims to bolster the company’s capital for future growth and operations, an enticing prospect for investors eyeing opportunities in the biotech sector. The shares will be issued and sold as per the terms approved by the company’s board.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.
